NCT02240446 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, Saoud M, Mechri A, Poulet E
Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012 Jul;169(7):719-24. doi: 10.1176/appi.ajp.2012.11071091. Erratum in: Am J Psychiatry. 2012 Dec 1;169(12):1321.
Hugdahl K, Nygård M, Falkenberg LE, Kompus K, Westerhausen R, Kroken R, Johnsen E, Løberg EM
Failure of attention focus and cognitive control in schizophrenia patients with auditory verbal hallucinations: evidence from dichotic listening. Schizophr Res. 2013 Jul;147(2-3):301-9. doi: 10.1016/j.schres.2013.04.005. Epub 2013 May 9.
Lawrie SM, Buechel C, Whalley HC, Frith CD, Friston KJ, Johnstone EC
Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry. 2002 Jun 15;51(12):1008-11.
Thomsen T, Rimol LM, Ersland L, Hugdahl K
Dichotic listening reveals functional specificity in prefrontal cortex: an fMRI study. Neuroimage. 2004 Jan;21(1):211-8.

Non-Invasive Brain Stimulation for Clinical Intervention for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients

Clinical trial NCT02240446 - References